Respiratory syncytial virus (RSV) has not been widely studied in the outpatient, adult setting, as symptoms have been similar ...

Respiratory syncytial virus activity is still high in parts of the country amid an unusually late season. Here's where rates ...

Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...

ST. PETERSBURG, Fla. — While the respiratory syncytial virus, known as RSV, is often thought of as a childhood issue, experts said many overlook its impact on adults. As a result, the Centers for ...

—These investigators found that during a recent winter in England, symptoms and outcomes among older patients with RSV mimicked those seen with influenza. A new hospital-based surveillance study from ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are ...

Respiratory illnesses are on the rise throughout the United States, and health officials are warning of a tripledemic. They recommend taking action to mitigate the spread of airborne illnesses. Here's ...

After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration ...

The UK Health Security Agency (UKHSA) has reported that the respiratory syncytial virus (RSV) vaccine is around 82% effective in preventing hospitalisation among adults aged 75-79. The data come from ...